Seegene reports first quarter 2022 financial results

Q1 revenue up 10% QoQ to reach record quarterly high of KRW 451.5 billion Foundation for sales expansion strengthened through ‘3 Ct’ technology commercialization, Allplex™ RV Master Assay approval, increased PCR instrument sales “Seegene to secure future growth by targeting syndromic testing market, expanding U.S. operations, M&A” SEOUL, South Korea, May 13, 2022 /PRNewswire/ — […]
  • Q1 revenue up 10% QoQ to reach record quarterly high of KRW 451.5 billion
  • Foundation for sales expansion strengthened through ‘3 Ct’ technology commercialization, Allplex™ RV Master Assay approval, increased PCR instrument sales
  • “Seegene to secure future growth by targeting syndromic testing market, expanding U.S. operations, M&A”

SEOUL, South Korea, May 13, 2022 /PRNewswire/ — Seegene Inc. (KQ096530), South Korea’s leading molecular diagnostics (MDx) company, today reported first quarter revenue of KRW 451.5 billion and operating profit of KRW 199.7 billion.

Logo

Total sales rose 10% quarter-over-quarter to reach a record quarterly high, driven by increased PCR demand due to a surge of the Omicron variant. Operating profit was comparable to the previous quarter’s KRW 199.9 billion.

During the first quarter, Seegene developed ‘Allplex™ HPV HR Detection,’ the world’s first commercialized assay applying ‘3 Ct’ technology that enables reporting three Ct values in a single channel for quantitative analysis. Seegene also obtained approval from the European Union and Australia for ‘Allplex™ RV Master Assay’ that can simultaneously detect 19 different respiratory viruses, including COVID-19. The company also established a branch in South Africa.

As for PCR instruments, Seegene newly installed 360 real-time PCR detection systems and 261 workstations for extraction and PCR setup, for a combined 5,214 and 2,543 respectively worldwide, solidifying the foundation for expanded global sales.

The company has also created a team to ramp up ESG (Environmental, Social, Governance) management.

“As PCR demand is declining worldwide, it will likely impact our revenue,” said Robert Lee, Senior Vice President of Seegene’s IR and PR department, adding that “Seegene will secure future growth by targeting the syndromic testing market for respiratory viruses and other illnesses as well as expand the utilization of PCR testing with the company’s fully automated MDx system, AIOS.”

Going forward, Seegene plans to establish R&D and production facilities within the United States to bolster operations and pursue M&A to achieve mid-to-long term growth.

Logo – https://mma.prnewswire.com/media/1357790/Seegene_logo_Logo.jpg

Total
0
Shares
Previous Article

‫ تكشف هواوي عن حلول جديدة ذكية لجميع السيناريوهات لتخزين الطاقة الكهروضوئية والطاقة في Intertersolar Europe 2022

Next Article

FP7McCann and Annahar Newspaper Launch Bold ‘Sell Your Vote’ Campaign in the Lead up to the Lebanese Elections

Related Posts

Conagen unveils commercial production of high-purity non-GMO salidroside

Ideal for adaptogen supplement solutions and natural preservatives in food and beverages. Bedford, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Conagen announced the commercialization of its 99% high-purity salidroside made by bioconversion technology, an active ingredient from the herbal plant Rhodiola rosea (golden root). Its strong antioxidant properties as an adaptogen are associated with reducing […]

Intelligent Chery TIGGO 7 PRO Hits Global Markets

CAIRO, June 9, 2021 /PRNewswire/ — Chery Automobile Co., Ltd., China’s top car export company for 18 consecutive years, has accelerated the upgrade of its smart technology with the launch of the PRO series models. As the first blockbuster product in the series, the TIGGO 7 PRO has seen a surge in worldwide sales following […]

شركة مياكس وإس آي جي لإصدار تراخيص المؤشرات تُطلقان العقود الآجلة لمعدل الضرائب على الشركات في بورصة مينيابوليس للحبوب

حيث تهدف العقود الآجلة الجديدة إلى مساعدة المستثمرين على الإحاطة بالتغيرات المحتملة في معدلات الضرائب على الشركات وتعزز العقود الآجلة للضرائب على الشركات مجموعة منتجات مياكس لإدارة المخاطر الضريبية برينستون، نيو جيرسي ومينيابوليس،, 1 ديسمبر / كانون أول 2021  /PRNewswire/ — أعلنت شركة MIAX®، المشغل لبورصة الأوراق المالية والمنتجات والخدمات عالية الأداء ومجموعة إس آي […]

Acino significantly expands presence and capabilities in Latin America through acquisition of M8 Pharmaceuticals

Over 300 M8 employees, product portfolio and pipeline to enhance Acino’s footprint and strategic position in key Latin American markets. Zurich, Switzerland, Sept. 20, 2023 (GLOBE NEWSWIRE) — Acino, a Swiss pharmaceutical company headquartered in Zurich, today announced that it has entered into an agreement to acquire M8 Pharmaceuticals (M8), a fast-growing specialty biopharmaceutical company, […]